LENSAR, Inc. (LNSR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$8.31-3.37%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Lensar aims to grow recurring revenue by selling more systems. Revenue guidance is $12.6 million for Q2 2026. The company secured a credit line for capital needs. The stock price has risen 9% in the last month.
Lensar is still losing money and revenue fell from $16M to $13.4M. The CFO recently left and earnings have missed estimates. The merger with Alcon was terminated, showing challenges. Revenue growth may not recover as hoped.
The market expects about 18% revenue growth next year. Our fair value is near $17.50, reflecting cautious optimism. The stock trades at a discount to peers with high risk.
Breaks if: Loss of credit facility or inability to access capital
Entered into a Priority Credit Line Agreement with Wells Fargo to secure a revolving credit facility.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis is intact, supported by strong recent financial performance, but it carries high risk due to fragile earnings quality and potential market volatility.
The market seems to have priced in a justified valuation, reflecting weak execution quality but not fully accounting for the potential turbulence ahead. There is an expectations gap, indicating that the market is not overly optimistic about future performance.
Management is on track with priorities to grow recurring revenue and improve profitability, as evidenced by recent financial results. However, there is a near-term risk of earnings misses, which could impact sentiment and performance.
The long-term thesis hinges on management's ability to maintain growth in recurring revenue and profitability while navigating potential market challenges. Key factors include guidance updates and the performance of sector bellwethers that could influence LNSR's momentum.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. LENSAR reported strong earnings, exceeding expectations. It posted EPS of $0.10 and revenue of $16.5M. This marks its first profitable quarter. However, rising operating expenses may challenge future revenue growth. The company faces uncertainty in maintaining its momentum.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS worse than -$0.08 in FY 2026
Breaks if: Revenue falls below $12.6M in Q2 2026
Over the next 1 to 3 years, LNSR's performance will depend on effective management execution and external market conditions. Not investment advice.